CD8A and neoplasm: In vitro, MT110 exhibited a potent activity in killing EpCAM-overexpressing tumor cells by redirected unstimulated human peripheral T cells (CD4+ and CD8+).16, 62 MT110 was efficacious in three in vivo models (tumor growth inhibition and elimination of established tumors).16